8,290
-2.24%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medipost Co
Its shares trade on KOSDAQ under the ticker 078160.KQ. It has been listed since 29 July 2005. In the fiscal year to 31 December 2025, it reported revenue of ₩73.66bn and a net loss of ₩85.40bn. At that date it held total assets of ₩431.55bn and shareholders' equity of ₩249.02bn.
Medipost Co., Ltd. engages in the development and manufacture of stem cell biotechnology products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2005-07-29. The firm mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newborn’s cord blood exclusively for family’s use. The company also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 29 Jul 2005
- Website
- medi-post.co.kr ↗
Leadership
Pay as last reported
- Mr. Dong Jin HwangPresident, since 2006
- Mr. Won Yil OhChief Executive Officer, Director, since 2022
- Mr. Jang Won LeeVice President, Director, since 2011
- Ms. Su Jin ChoiManaging Director
- Ms. Hye Gyeong HongManaging Director
- Ms. Mi Hyeon JungAssistant Managing Director
- Mr. Seung Jin LeeAssistant Managing Director
- Mr. Hyeok Jun NamAssistant Managing Director
- Ms. Se Mi NamAssistant Managing Director
- Mr. Sang Je SungAssistant Managing Director
- Mr. Tae Ho YangAssistant Managing Director
- Mr. Byeong Su JungNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medipost operates public and family cord blood banks in South Korea.
- The company develops stem cell drugs for knee cartilage recovery and other treatments.
- Medipost provides healthcare food and natural cosmetics as part of its product portfolio.
Weaknesses
- Medipost's operations are limited to South Korea without international expansion.
- The company relies on cord blood banking as its primary business segment.
- Medipost does not have a global presence beyond Seongnam, South Korea.
Opportunities
- Expanding cord blood banking services to other Asian countries like Japan and China.
- Increasing demand for stem cell therapies in the growing Health Care sector.
- Growing market for healthcare food and natural cosmetics in South Korea.
Threats
- Competition from other cord blood banks in South Korea.
- Regulatory changes affecting stem cell drug approvals in South Korea.
- Economic downturns impacting healthcare spending in South Korea.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.